TGF- βinhibits IL-1β-activated PAR-2 expression through multiple pathways in human primary synovial cells

Shin Han Tsai, Ming Thau Sheu, Yu Chih Liang, Hsiu Tan Cheng, Sheng Shiung Fang, Chien Ho Chen

研究成果: 雜誌貢獻文章

13 引文 (Scopus)

摘要

To investigate the mechanism how Transforming growth factor-(TGF-) represses Interleukin-1 (IL-1)-induced Proteinase-Activated Receptor-2 (PAR-2) expression in human primary synovial cells (hPSCs). Human chondrocytes and hPSCs isolated from cartilages and synovium of Osteoarthritis (OA) patients were cultured with 10% fetal bovine serum media or serum free media before treatment with IL-1, TGF-1, or Connective tissue growth factor (CTGF). The expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. Collagen zymography was performed to assess the activity of Matrix metalloproteinases-13 (MMP-13). It was demonstrated that IL-1 induces PAR-2 expression via p38 pathway in hPSCs. This induction can be repressed by TGF- and was observed to persist for at least 48 hrs, suggesting that TGF- inhibits PAR-2 expression through multiple pathways. First of all, TGF- was able to inhibit PAR-2 activity by inhibiting IL-1-induced p38 signal transduction and secondly the inhibition was also indirectly due to MMP-13 inactivation. Finally, TGF- was able to induce CTGF, and in turn CTGF represses PAR-2 expression by inhibiting IL-1-induced phospho-p38 level. TGF- could prevent OA from progression with the anabolic ability to induce CTGF production to maintain extracellular matrix (ECM) integrity and to down regulate PAR-2 expression, and the anti-catabolic ability to induce Tissue inhibitors of metalloproteinase-3 (TIMP-3) production to inhibit MMPs leading to avoid PAR-2 over-expression. Because IL-1-induced PAR-2 expressed in hPSCs might play a significantly important role in early phase of OA, PAR-2 repression by exogenous TGF- or other agents might be an ideal therapeutic target to prevent OA from progression.
原文英語
文章編號97
期刊Journal of Biomedical Science
16
發行號1
DOIs
出版狀態已發佈 - 2009

指紋

PAR-2 Receptor
Interleukin-1
Connective Tissue Growth Factor
Osteoarthritis
Matrix Metalloproteinase 13
Tissue Inhibitor of Metalloproteinase-3
Signal transduction
Synovial Membrane
Polymerase chain reaction
RNA-Directed DNA Polymerase
Serum-Free Culture Media
Cartilage
Transforming Growth Factors
Chondrocytes
Reverse Transcriptase Polymerase Chain Reaction
Matrix Metalloproteinases
Extracellular Matrix
Signal Transduction
Collagen
Down-Regulation

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Molecular Biology
  • Cell Biology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism
  • Pharmacology (medical)

引用此文

TGF- βinhibits IL-1β-activated PAR-2 expression through multiple pathways in human primary synovial cells. / Tsai, Shin Han; Sheu, Ming Thau; Liang, Yu Chih; Cheng, Hsiu Tan; Fang, Sheng Shiung; Chen, Chien Ho.

於: Journal of Biomedical Science, 卷 16, 編號 1, 97, 2009.

研究成果: 雜誌貢獻文章

@article{2eabde302d4f4bd0a240db881fbce0a4,
title = "TGF- βinhibits IL-1β-activated PAR-2 expression through multiple pathways in human primary synovial cells",
abstract = "To investigate the mechanism how Transforming growth factor-(TGF-) represses Interleukin-1 (IL-1)-induced Proteinase-Activated Receptor-2 (PAR-2) expression in human primary synovial cells (hPSCs). Human chondrocytes and hPSCs isolated from cartilages and synovium of Osteoarthritis (OA) patients were cultured with 10{\%} fetal bovine serum media or serum free media before treatment with IL-1, TGF-1, or Connective tissue growth factor (CTGF). The expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. Collagen zymography was performed to assess the activity of Matrix metalloproteinases-13 (MMP-13). It was demonstrated that IL-1 induces PAR-2 expression via p38 pathway in hPSCs. This induction can be repressed by TGF- and was observed to persist for at least 48 hrs, suggesting that TGF- inhibits PAR-2 expression through multiple pathways. First of all, TGF- was able to inhibit PAR-2 activity by inhibiting IL-1-induced p38 signal transduction and secondly the inhibition was also indirectly due to MMP-13 inactivation. Finally, TGF- was able to induce CTGF, and in turn CTGF represses PAR-2 expression by inhibiting IL-1-induced phospho-p38 level. TGF- could prevent OA from progression with the anabolic ability to induce CTGF production to maintain extracellular matrix (ECM) integrity and to down regulate PAR-2 expression, and the anti-catabolic ability to induce Tissue inhibitors of metalloproteinase-3 (TIMP-3) production to inhibit MMPs leading to avoid PAR-2 over-expression. Because IL-1-induced PAR-2 expressed in hPSCs might play a significantly important role in early phase of OA, PAR-2 repression by exogenous TGF- or other agents might be an ideal therapeutic target to prevent OA from progression.",
author = "Tsai, {Shin Han} and Sheu, {Ming Thau} and Liang, {Yu Chih} and Cheng, {Hsiu Tan} and Fang, {Sheng Shiung} and Chen, {Chien Ho}",
year = "2009",
doi = "10.1186/1423-0127-16-97",
language = "English",
volume = "16",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - TGF- βinhibits IL-1β-activated PAR-2 expression through multiple pathways in human primary synovial cells

AU - Tsai, Shin Han

AU - Sheu, Ming Thau

AU - Liang, Yu Chih

AU - Cheng, Hsiu Tan

AU - Fang, Sheng Shiung

AU - Chen, Chien Ho

PY - 2009

Y1 - 2009

N2 - To investigate the mechanism how Transforming growth factor-(TGF-) represses Interleukin-1 (IL-1)-induced Proteinase-Activated Receptor-2 (PAR-2) expression in human primary synovial cells (hPSCs). Human chondrocytes and hPSCs isolated from cartilages and synovium of Osteoarthritis (OA) patients were cultured with 10% fetal bovine serum media or serum free media before treatment with IL-1, TGF-1, or Connective tissue growth factor (CTGF). The expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. Collagen zymography was performed to assess the activity of Matrix metalloproteinases-13 (MMP-13). It was demonstrated that IL-1 induces PAR-2 expression via p38 pathway in hPSCs. This induction can be repressed by TGF- and was observed to persist for at least 48 hrs, suggesting that TGF- inhibits PAR-2 expression through multiple pathways. First of all, TGF- was able to inhibit PAR-2 activity by inhibiting IL-1-induced p38 signal transduction and secondly the inhibition was also indirectly due to MMP-13 inactivation. Finally, TGF- was able to induce CTGF, and in turn CTGF represses PAR-2 expression by inhibiting IL-1-induced phospho-p38 level. TGF- could prevent OA from progression with the anabolic ability to induce CTGF production to maintain extracellular matrix (ECM) integrity and to down regulate PAR-2 expression, and the anti-catabolic ability to induce Tissue inhibitors of metalloproteinase-3 (TIMP-3) production to inhibit MMPs leading to avoid PAR-2 over-expression. Because IL-1-induced PAR-2 expressed in hPSCs might play a significantly important role in early phase of OA, PAR-2 repression by exogenous TGF- or other agents might be an ideal therapeutic target to prevent OA from progression.

AB - To investigate the mechanism how Transforming growth factor-(TGF-) represses Interleukin-1 (IL-1)-induced Proteinase-Activated Receptor-2 (PAR-2) expression in human primary synovial cells (hPSCs). Human chondrocytes and hPSCs isolated from cartilages and synovium of Osteoarthritis (OA) patients were cultured with 10% fetal bovine serum media or serum free media before treatment with IL-1, TGF-1, or Connective tissue growth factor (CTGF). The expression of PAR-2 was detected using reverse transcriptase-polymerase chain reaction (RT-PCR) and western blotting. Collagen zymography was performed to assess the activity of Matrix metalloproteinases-13 (MMP-13). It was demonstrated that IL-1 induces PAR-2 expression via p38 pathway in hPSCs. This induction can be repressed by TGF- and was observed to persist for at least 48 hrs, suggesting that TGF- inhibits PAR-2 expression through multiple pathways. First of all, TGF- was able to inhibit PAR-2 activity by inhibiting IL-1-induced p38 signal transduction and secondly the inhibition was also indirectly due to MMP-13 inactivation. Finally, TGF- was able to induce CTGF, and in turn CTGF represses PAR-2 expression by inhibiting IL-1-induced phospho-p38 level. TGF- could prevent OA from progression with the anabolic ability to induce CTGF production to maintain extracellular matrix (ECM) integrity and to down regulate PAR-2 expression, and the anti-catabolic ability to induce Tissue inhibitors of metalloproteinase-3 (TIMP-3) production to inhibit MMPs leading to avoid PAR-2 over-expression. Because IL-1-induced PAR-2 expressed in hPSCs might play a significantly important role in early phase of OA, PAR-2 repression by exogenous TGF- or other agents might be an ideal therapeutic target to prevent OA from progression.

UR - http://www.scopus.com/inward/record.url?scp=72449175224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449175224&partnerID=8YFLogxK

U2 - 10.1186/1423-0127-16-97

DO - 10.1186/1423-0127-16-97

M3 - Article

VL - 16

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 1

M1 - 97

ER -